share_log

6-K: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business Eps Guidance Raised Due to Strong Business Performance

6-K: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business Eps Guidance Raised Due to Strong Business Performance

6-K:疫苗銷售早於預期,銷售額增長15.7%;業務表現強勁,2024年業務每股收益指導上調
美股SEC公告 ·  10/25 12:42
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息